Analyst Ratings For NASDAQ:GTHX – G1 Therapeutics (NASDAQ:GTHX)
Today, Needham & Company LLC raised its price target on NASDAQ:GTHX – G1 Therapeutics (NASDAQ:GTHX) to per share.
Some recent analyst ratings include
- 3/7/2018-BTIG Research Reiterated Rating of Buy.
- 3/6/2018-JPMorgan Chase Reiterated Rating of Overweight ➝ Overweight.
- 3/5/2018-Cowen Reiterated Rating of Buy.
- 6/12/2017-Wedbush initiated coverage with a Outperform rating.
Recent Insider Trading Activity For NASDAQ:GTHX – G1 Therapeutics (NASDAQ:GTHX)
NASDAQ:GTHX – G1 Therapeutics (NASDAQ:GTHX) has insider ownership of 15.92% and institutional ownership of 42.11%.
- On 5/15/2018 Mark A Velleca, Insider, sold 7,500 with an average share price of $46.28 per share and the total transaction amounting to $347,100.00.
- On 5/7/2018 Jennifer K Moses, VP, sold 750 with an average share price of $45.00 per share and the total transaction amounting to $33,750.00.
- On 4/16/2018 Mark A Velleca, Insider, sold 7,500 with an average share price of $36.00 per share and the total transaction amounting to $270,000.00.
- On 4/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $37.47 per share and the total transaction amounting to $28,102.50.
- On 3/15/2018 Rajesh Malik, Insider, sold 3,776 with an average share price of $38.18 per share and the total transaction amounting to $144,167.68.
- On 3/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $26.55 per share and the total transaction amounting to $19,912.50.
- On 2/15/2018 Rajesh Malik, Insider, sold 3,776 with an average share price of $20.00 per share and the total transaction amounting to $75,520.00.
Recent Trading Activity for NASDAQ:GTHX – G1 Therapeutics (NASDAQ:GTHX)
Shares of NASDAQ:GTHX – G1 Therapeutics closed the previous trading session at 52.49 up +4.18 8.65% with 48.7400016784668 shares trading hands.